[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100424514":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":28,"locations":37,"responsibleParty":56,"collaborators":58,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":27,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":39,"whyStopped":27,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Maimonides Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vaginal Testosterone Cream Arm","EXPERIMENTAL","Women enrolled in this arm will receive vaginal testosterone cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.",[13],"Drug: Vaginal Cream with Applicator",{"label":15,"type":16,"description":17,"interventionNames":18},"Vaginal Placebo Cream Arm","PLACEBO_COMPARATOR","Women enrolled in this arm will receive vaginal placebo cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Vaginal Cream with Applicator","Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.",[15,9],[26],"Testosterone Cream",null,[29,34],{"name":30,"role":31,"phone":32,"phoneExt":27,"email":33},"Alison Polland, MD","CONTACT","(718) 283-7770","apolland@maimonidesmed.org",{"name":35,"role":31,"phone":27,"phoneExt":27,"email":36},"Mariela Martinez, MD","mmrivera@maimonidesmed.org",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Brooklyn","New York","11219","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-73.94958,40.6501,{"lat":49,"lon":48},[52,54],{"name":30,"role":31,"phone":53,"phoneExt":27,"email":33},"718-283-7770",{"name":30,"role":55,"phone":27,"phoneExt":27,"email":27},"PRINCIPAL_INVESTIGATOR",{"type":57,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR",[59],{"name":60,"class":6},"American Urological Association","100424514","phase-4-prevention-of-recurrent-uti-using-vaginal-testosterone-versus-placebo-placebo-100424514",false,"NCT04807894","Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo","Prevention of Recurrent Urinary Tract Infection Using Vaginal Testosterone Versus Placebo","PIVoT","Inclusion Criteria:\n\n* 60-90 yo Female\n* Postmenopausal\n* Recurrent UTIs (three or more culture confirmed symptomatic episodes of UTI or two or more in the past 6 months).\n* English Proficiency\n* Unable or unwilling to use topical estrogen.\n* Patients with history of or current endometrial or breast cancer and current aromatase inhibitor therapy may also be included in study.\n* Patient on oral estrogen therapy may be included.\n* Patient with slings, prior vaginal surgery or pessary may be included.\n\nExclusion Criteria:\n\n* Current UTI\u002F Dipstick and culture positive (\\> trace leukocytes or nitrites)\n* Antibiotic (vaginal or oral) use in the last 4 weeks\n* Current sexually transmitted infection\n* Chronic Foley catheter use or chronic ureteral stent placement.\n* Vaginal probiotic use in the last 4 weeks\n* Patient currently using vaginal estrogen.\n* Post-void Residual Volume \\>150 mL or current diagnosis of urinary retention\n* Non-evaluated hematuria (\\> trace on dipstick, microscopic, gross)\n* Unable to complete study tasks or comply with follow up.",true,"FEMALE","60 Years","90 Years",{"count":74,"type":75},100,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","Women over the age of 60 years have an estimated 10 to 15 % risk of recurrent urinary tract infections (UTI). This is believed to be due to hormonally induced changes in the vaginal flora associated with menopause. After menopause, there is a chemical changes in the vagina that may predispose to bacterial infections.\n\nThe role of vaginal estrogen creams to restore vaginal atrophy and prevent urinary tract infections has been well characterized. Vaginal testosterone (VT) application use in postmenopausal breast cancer patients on aromatase inhibitors have been shown to improve vaginal pH, vaginal atrophy symptom scores, dyspareunia, and vaginal dryness. Although testosterone has been used to improve sexual function in postmenopausal women, the effects of VT on vaginal flora and recurrent UTIs are unknown.\n\nThe purpose of this study is to determine whether topically applied vaginal testosterone cream is more effective than placebo in reducing the incidence of urinary tract infections in postmenopausal women with recurrent urinary tract infections and to ascertain the effects of topical estrogen on the vaginal pH and flora.",[81,82,83],"Recurrent Urinary Tract Infection","Vaginal Atrophy","Postmenopausal Disorder",[85,86,87,88],"urinary tract infections,","postmenopausal women","vaginal atrophy,","vaginal flora","2025-11-04",{"date":91,"type":92},"2025-11-05","ACTUAL",{"date":94,"type":92},"2020-11-01",{"date":96,"type":75},"2026-12-31",{"name":5,"class":6},1]